OncoMatch/Clinical Trials/NCT05727176
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Is NCT05727176 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TAS-120 for advanced cholangiocarcinoma.
Treatment: TAS-120 — This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: FGFR2 fusion
Required: FGFR2 rearrangement
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: gemcitabine and platinum-based regimen
Received at least one prior systemic gemcitabine and platinum-based regimen for CCA; Documentation of radiographic disease progression on the most recent prior therapy
Cannot have received: FGFR-directed therapy
Patients with prior FGFR-directed therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Diego UCSD - Moores Cancer Center · La Jolla, California
- Tampa General Hospital Cancer Institute · Tampa, Florida
- Henry Ford Health System · Detroit, Michigan
- Gabrail Cancer Center Research · Canton, Ohio
- Texas Oncology · Abilene, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify